Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Randomized Double-blind
100%
Placebo-controlled
100%
Maintenance Treatment
100%
Recurrent Ovarian Carcinoma
100%
Rucaparib
100%
Phase 3 Trial
100%
Control Phase
100%
Platinum-based Therapy
100%
Placebo
44%
Platinum-based Chemotherapy
44%
Placebo Groups
33%
Carcinoma
33%
Platinum-based
33%
BRCA mutation
33%
PARP Inhibitors (PARPi)
33%
Complete Response
22%
Partial Response
22%
Intention-to-treat
22%
Loss of Heterozygosity
22%
Progression-free Survival
22%
Platinum-resistant Ovarian Cancer
22%
Platinum Sensitivity
22%
Homologous Recombination Deficiency
22%
Hospital Center
11%
Anemia
11%
Hazard Ratio
11%
Oncology
11%
Performance Status
11%
Gene mutation
11%
Cancer Center
11%
Chemotherapy Regimen
11%
Ovarian Carcinoma
11%
Anticancer Activity
11%
Previous Treatment
11%
Hemoglobin Concentration
11%
Organ Function
11%
Aspartate Aminotransferase
11%
Endometrioid
11%
Twice Daily
11%
Alanine Aminotransferase
11%
Anticancer Therapy
11%
Mutation Status
11%
Standard of Care
11%
Treatment Setting
11%
Best Response
11%
Upper Normal Limit
11%
Carbohydrate Antigen 125 (CA125)
11%
Fallopian Tube Carcinoma
11%
Step-down
11%
Germline BRCA mutation
11%
Progression-free Interval
11%
Block Size
11%
CNS Metastases
11%
Primary Peritoneal
11%
High-grade Serous
11%
Homologous Recombination Repair Genes
11%
BRCA Wild-type
11%
Clovis
11%
Median Progression-free Survival
11%
Treatment-related Adverse Events
11%
High Loss
11%
Medicine and Dentistry
Krukenberg Tumor
100%
Placebo
100%
Maintenance Therapy
100%
Rucaparib
100%
Platinum
100%
Progression Free Survival
40%
Chemotherapy
40%
Carcinoma
30%
PARP Inhibitor
30%
Homologous Recombination
30%
BRCA Mutation
30%
Intention-to-Treat Analysis
20%
Heterozygosity
20%
Platinum-Sensitive Ovarian Cancer
20%
Anemia
10%
Malignant Neoplasm
10%
Gene Mutation
10%
Adverse Event
10%
Hazard Ratio
10%
Somatics
10%
Oncology
10%
Antineoplastic Activity
10%
Tumor Antigen
10%
Hemoglobin Determination
10%
Cancer Treatment
10%
Alanine Aminotransferase
10%
Aspartate Aminotransferase
10%
Central Nervous System Metastasis
10%
Uterine Tube Carcinoma
10%
Recombination Repair
10%
Germ Cell
10%
Oral
10%